XML 25 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS’ (DEFICIT) EQUITY
6 Months Ended
Sep. 30, 2022
Equity [Abstract]  
STOCKHOLDERS’ (DEFICIT) EQUITY

NOTE 6 – STOCKHOLDERS’ (DEFICIT) EQUITY

During the six month period ended September 30, 2022, no warrants were exercised, and no shares were issued.

 

During the six month period ended September 30, 2021, 366,892 warrants were exercised generating gross proceeds of $2,963,658. There were a total of 1,573,098 warrants outstanding at this date. No other shares were issued in the period.

 

Loss per share

The following table sets forth the computation of basic and diluted loss per share for the periods indicated.

                    
   Three Months Ended September 30,   Six Months Ended September 30, 
   2022   2021   2022   2021 
    (in Dollars, except Share Amounts)    (in Dollars, except Share Amounts) 
Net loss attributable to common stockholders   (4,078,477)   (3,494,264)   (8,057,774)   (6,837,989)
Weighted average basic and diluted shares outstanding   24,102,866    23,308,049    24,102,866    23,209,514 
Basic and diluted loss per share:   (0.17)   (0.15)   (0.33)   (0.29)

 

The Company excludes warrants outstanding, which are anti-dilutive given the Company is in a loss position, from the basic and diluted loss per share calculation.

Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding during the period. For the three and six month periods ended September 30, 2022, warrants to purchase 1,573,098 shares of common stock and a unit purchase option to purchase 9,710 shares of common stock, as well as warrants to purchase 9,710 shares of common stock, were considered anti-dilutive and were excluded from the calculation of diluted loss per share. For the three and six month periods ended September 30, 2021, warrants to purchase 1,940,740 shares of common stock and a unit purchase option to purchase 9,710 shares of common stock, as well as warrants to purchase 9,710 shares of common stock, were considered anti-dilutive and were also excluded from the calculation of diluted loss per share.